Table 3.
Traditional preventive treatment patterns in OVERCOME (EU) migraine cohort and in survey respondents eligible for migraine preventive medication (excluding calcitonin gene-related peptide-monoclonal antibody users)
| OVERCOME (EU) migraine cohort |
0–3 HD/m (n = 13,759) |
4–7 HD/m (n = 4203) |
8–14 HD/m (n = 1730) |
≥ 15 HD/m (n = 1064) |
Total (N = 20,756) |
| Currentlyb using preventives,c n (%) | |||||
| 1 preventive | 943 (6.9) | 358 (8.5) | 171 (9.9) | 129 (12.1) | 1601 (7.7) |
| 2 preventives | 514 (3.7) | 188 (4.5) | 92 (5.3) | 68 (6.4) | 862 (4.2) |
| ≥ 3 preventives | 1475 (10.7) | 463 (11.0) | 186 (10.8) | 123 (11.6) | 2247 (10.8) |
| Currentb preventive medication category,c n (%) – not mutually exclusive | |||||
| Antiseizured | 1793 (13.0) | 604 (14.4) | 235 (13.6) | 171 (16.1) | 2803 (13.5) |
| Antidepressante | 1903 (13.8) | 628 (14.9) | 282 (16.3) | 198 (18.6) | 3011 (14.5) |
| Antihypertensivef | 2011 (14.6) | 649 (15.4) | 284 (16.4) | 180 (16.9) | 3124 (15.1) |
| Onabotulinum toxin A | 322 (2.3) | 94 (2.2) | 45 (2.6) | 29 (2.7) | 490 (2.4) |
| Survey respondents eligible for migraine preventive medicationa | N/A |
4–7 HD/m (n = 1458) |
8–14 HD/m (n = 792) |
≥ 15 HD/m (n = 499) |
Total (N = 2749) |
| Currentlyb using preventives,c n (%) | |||||
| 1 preventive | 173 (11.9) | 97 (12.2) | 79 (15.8) | 349 (12.7) | |
| 2 preventives | 73 (5.0) | 50 (6.3) | 41 (8.2) | 164 (6.0) | |
| ≥ 3 preventives | 104 (7.1) | 59 (7.4) | 41 (8.2) | 204 (7.4) | |
| Currentb preventive medication category,c n (%) – not mutually exclusive | |||||
| Antiseizured | 170 (11.7) | 99 (12.5) | 72 (14.4) | 341 (12.4) | |
| Antidepressante | 201 (13.8) | 115 (14.5) | 99 (19.8) | 415 (15.1) | |
| Antihypertensivef | 202 (13.9) | 121 (15.3) | 80 (16.0) | 403 (14.7) | |
| Onabotulinum toxin A | 37 (2.5) | 18 (2.3) | 12 (2.4) | 67 (2.4) | |
CGRP-mAbs calcitonin gene-related peptide-monoclonal antibodies, HD/m headache days per month, MIDAS Migraine Disability Assessment
aPatients with ≥ 4 HD/m on average over the last 90 days and ≥ 11 (MIDAS). Users of CGRP-mAbs are excluded
bCurrent defined as taken or used in the last three months for preventive medications
cExcluding CGRP-mAbs
dAntiseizure medications included valproic acid/valproate, gabapentin, pregabalin, topiramate, zonisamide, levetiracetam, clonazepam, lamotrigine, carbamazepine, oxcarbazepine and ‘other antiseizure medication’. Not all medications are licensed in both Germany and Spain
eAntidepressant medications included amitriptyline, desvenlafaxine, doxepin, escitalopram, fluoxetine, imipramine, nortriptyline, paroxetine, sertraline, venlafaxine, clomipramine, trazodone, mianserin, fluvoxamine, sulpiride, mirtazapine, citalopram, opipramol and ‘other antidepressant medication’. Not all medications are licensed in both Germany and Spain
fAntihypertensive medications included atenolol, candesartan, lisinopril, metoprolol, nifedipine, propranolol, verapamil, diltiazem, nicardipine, captopril, enalapril, telmisartan and ‘other blood pressure or heart medication’. Not all medications are licensed in both Germany and Spain